Factors such as the high prevalence of coronary heart disease, rising incidence of diabetes, and lifestyle changes provide suitable backgrounds for the development of market growth. However, the high cost of therapeutic surgeries and side effects related to medications are projected to restrain the market growth during the forecast period.
Myocardial ischemia is a common occurrence and occurs with increased frequency in patients with diabetes due to cardiac autonomic dysfunction. According to a study published in the Endocrinology, Diabetes & Metabolism Case Reports journal in 2013, ~22% of the patients diagnosed with type 2 diabetes were estimated to suffer from Silent Myocardial Ischemia (SMI). Moreover, it is reported that the prevalence of diabetes has increased.
This is illustrative by the fact sheet of the World Health Organization (WHO) published in 2017. According to it, the global prevalence of diabetes among individuals ages 18 years or more was about 8.5% in 2014. Thus, it is interpreted that the rising prevalence of diabetes provides a necessary driving force for the myocardial ischemia market to expand.
The myocardial ischemia market has been segmented into type, treatment & diagnosis, and end user. By type, the market has been bifurcated into symptomatic and asymptomatic.
Based on treatment & diagnosis, the market has been divided into diagnosis and treatment. Diagnosis segment has been further segregated into imaging and stress test.
The treatment has been further divided into medications and surgery. By end-user, the market has been classified as hospitals & clinics, diagnostic centers, ambulatory surgery centers, and others. The hospitals and clinics accounted for a market value of USD 18,744.2 million in 2023.
The prominent players in the myocardial ischemia market are:
Some of the key strategies followed by the players operating in the myocardial ischemia market were innovation, product development, acquisition, and expansion.
The myocardial ischemia market, based on region, has been divided into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The Americas is estimated to dominate the brain ischemia ischemiamarket during the forecast period. Americas accounts for the largest regional market owing to the rising prevalence of diabetes, obesity, physical inactivity, and excessive alcohol use among the population.
The European market for myocardial ischemia is expected to be the second-largest during the forecast period. The high growth rate is due to the high incidence rate of cardiovascular diseases in Europe. According to the European Cardiovascular Disease Statistics 2017, 45% of deaths in Europe is due to cardiovascular diseases (CVD).
Additionally, the companies operating in the market are mainly focusing on mergers and acquisition, which is expected to support market growth. Asia-Pacific is estimated to be the fastest-growing market due to the rising prevalence of diabetes. According to the Asian Diabetes Prevention Initiative, 60% of the world’s diabetic patient live in Asia. Such high incidences of diabetes that lead to silent myocardial ischemia are likely to fuel the market growth.
Moreover, in the Asia-Pacific region, China accounted for a market share of 23.5% in 2017. However, the Middle East and Africa are expected to observe slow growth due to less exposure to healthcare services and stringent government rules and regulations.
Key Updates
Available Additional Customizations
Intended Audience
| Report Attribute/Metric | Details |
| Market Size | 2032: USD 1.5 Billion |
| CAGR | 7.50% (2024-2032) |
| Base Year | 2023 |
| Forecast Period | 2024-2032 |
| Historical Data | 2022 |
| Forecast Units | Value (USD Billion) |
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Type, Treatment & Diagnosis, End User |
| Geographies Covered | North America, Europe, Asia-Pacific, and Rest of the World (RoW) |
| Key Vendors | Taxus Cardium (US), ViroMed Co. Ltd. (Republic of Korea ), Edward Lifesciences (US), Daiichi Sankyo Company Limited (Japan), Boston Scientific Corporation (US), Merck KGaA (Germany), Novartis AG (Switzerland), Boehringer Ingelheim International GmbH (Germany), Johnson & Johnson Services Inc. (US), Bayer AG (Germany), and AstraZeneca (UK). |
| Key Market Opportunities | New product launches and R&D Amongst major key Players |
| Key Market Drivers | · Rising prevalence of diabetes · The increasing cases of coronary artery disease and diabetes · Growing awareness related to heart conditions · Technological advancement in treatments · Rising numbers of hospitals and healthcare infrastructure |
Myocardial Ischemia Market Highlights:
Frequently Asked Questions (FAQ) :
Myocardial ischemia market projected to grow at approximately 7.50% CAGR during the assessment period (2024-2032).
The valuation of the myocardial ischemia market is estimated to increase to USD 1.5 Billion by the end of 2032.
Increasing awareness about heart conditions, technological advancement in medical science, and rising numbers of hospitals & healthcare infrastructure, are major tailwinds pushing the growth of the global myocardial ischemia market.
North America holds the largest share in the myocardial ischemia market, followed by Europe and the Asia Pacific, respectively.
ViroMed Co. Ltd. (Korea), Johnson & Johnson Services Inc. (US), Boehringer Ingelheim International GmbH (Germany), Taxus Cardium (US), Bayer AG (Germany), Daiichi Sankyo Company Limited (Japan), AstraZeneca (UK), Edward Lifesciences (US), Boston Scientific Corporation (US), Novartis AG (Switzerland), and Merck KGaA (Germany), are some of the top players operating in the myocardial ischemia market.
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
